Asthma results from a prolonged inflammatory process affecting the airways and, as in other forms of COPD, a variety of mediator driven pathways are involved.

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Dr Zaheer Mangera shares insights into the lung cancer pathway and the benefits and challenges of early diagnosis and lung ...